摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-(4-苯基噻唑-2-基)乙酸 | 38107-10-7

中文名称
2-(4-苯基噻唑-2-基)乙酸
中文别名
4-苯基-2-噻唑乙酸
英文名称
4-phenylthiazole-2-ylacetic acid
英文别名
(4-phenyl-thiazol-2-yl)-acetic acid;α-(4-Phenyl-2-thiazolyl)essigsaeure;4-Phenylthiazol-2-essigsaeure;2-(4-Phenylthiazol-2-YL)acetic acid;2-(4-phenyl-1,3-thiazol-2-yl)acetic acid
CAS
38107-10-7
化学式
C11H9NO2S
mdl
——
分子量
219.264
InChiKey
OLQHHTZTEVMZLC-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    90-91℃
  • 密度:
    1.329

计算性质

  • 辛醇/水分配系数(LogP):
    2.1
  • 重原子数:
    15
  • 可旋转键数:
    3
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.09
  • 拓扑面积:
    78.4
  • 氢给体数:
    1
  • 氢受体数:
    4

SDS

SDS:53dfae42046f1eee9674d47218d09ee5
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Novel compounds and compositions as protease inhibitors
    申请人:——
    公开号:US20020052378A1
    公开(公告)日:2002-05-02
    The present invention relates to novel cysteine protease inhibitors of Formula I: 1 the pharmaceutically acceptable salts and N-oxide derivatives thereof, their use as therapeutic agents and methods of making them.
    本发明涉及一种新型半胱酸蛋白酶抑制剂的化学式I: 1 其药用盐及N-氧化物衍生物,它们作为治疗剂的用途以及制备它们的方法。
  • Studies of heterocyclic compounds. VII. The reactions of 5,6-dihydrothiazolo(2,3-b)thiazolium salts with carbanions.
    作者:HIROKO OHTSUKA、TADASHI MIYASAKA、KIICHI ARAKAWA
    DOI:10.1248/cpb.23.3254
    日期:——
    The reaction of 5, 6-dihydrothiazolo [2, 3-b] thiazolium salt (1) with the sodium salt of acetylacetone furnished 3-(2-thiazolyl)-acetylacetone (2) with elimination of thiirane and 2-acetonylidene-3-acetylthioethyl-4-thiazoline (3). The reaction of 1 with the sodium salt of ethyl acetoacetate gave ethyl 2-(2-thiazolyl)-acetoacetate (12) and the reaction of 1 with the sodium salts of ethyl cyanoacetate and malononitrile gave 2-substituted thiazole (16), 3-(2-mercaptoethyl)-thiazoline (17) and/or its disulfide (18). The tautomeric forms of 2, 12 and 16 are discussed on the basis of the structures of the methylated products and of their spectrophotometric properties.
    5,6-二氢噻唑并[2,3-b]噻唑盐(1)与乙酰乙酸反应,生成3-(2-噻唑基)乙酰乙酸(2),同时脱去环丙烷和2-丙酮亚甲基-3-乙酰乙基-4-噻唑啉(3)。1与乙酰乙酸乙酯钠盐反应得到乙基2-(2-噻唑基)乙酰乙酸酯(12),而1与氰乙酸乙酯钠盐和丙二腈钠盐反应则生成2-取代噻唑(16)、3-(2-巯基乙基)噻唑啉(17)及其二硫化物(18)。根据甲基化产物的结构及其分光光度特性,讨论了2、12和16的互变异构形式。
  • [EN] IMIDAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS<br/>[FR] COMPOSES D'IMIDAZOLE DESTINES AU TRAITEMENT DE TROUBLES NEURODEGENERATIFS
    申请人:PFIZER PROD INC
    公开号:WO2005092864A1
    公开(公告)日:2005-10-06
    The present invention relates to compounds of the Formula (I) wherein R1, R2, R3, R4, R5, R6, R7 and A are as defined. Compounds of the Formula (I) have activity inhibiting production of Aβ-peptide. The invention also relates to pharmaceutical compositions and methods for treating diseases and disorders, for example, neurodegenerative and/or neurological disorders, e.g., Alzheimer’s disease, in a mammal comprising compounds of the Formula (I).
    本发明涉及式(I)的化合物,其中R1、R2、R3、R4、R5、R6、R7和A的定义如上所述。式(I)的化合物具有抑制Aβ肽产生的活性。本发明还涉及制药组合物和治疗疾病和障碍的方法,例如,神经退行性和/或神经系统疾病,例如阿尔茨海默病,在哺乳动物中包括式(I)的化合物。
  • [EN] NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS<br/>[FR] NOUVEAUX COMPOSES ET COMPOSITIONS UTILISES COMME INHIBITEURS DE PROTEASE
    申请人:MERCK FROSST CANADA INC
    公开号:WO2001049288A1
    公开(公告)日:2001-07-12
    The present invention relates to novel cysteine protease inhibitors of Formula (I), the pharmaceutically acceptable salts and N-oxide derivatives thereof, their use as therapeutic agents and methods of making them.
    本发明涉及公式(I)的新型半胱酸蛋白酶抑制剂、其药学上可接受的盐和N-氧化物衍生物,它们的用途作为治疗剂以及制备它们的方法。
  • Imidazole compounds for the treatment of neurodegenerative disorders
    申请人:Brodney A. Michael
    公开号:US20050215610A1
    公开(公告)日:2005-09-29
    The present invention relates to compounds of the Formula I wherein R 1 , R 2 , R 3 , R 4 , R 6 , R 7 and A are as defined. Compounds of the Formula I have activity inhibiting production of Aβ-peptide. The invention also relates to pharmaceutical compositions and methods for treating diseases and disorders, for example, neurodegenerative and/or neurological disorders, e.g., Alzheimer's disease, in a mammal comprising compounds of the Formula I.
    本发明涉及公式I中的化合物,其中R1、R2、R3、R4、R6、R7和A的定义如所述。公式I的化合物具有抑制Aβ肽生成活性。本发明还涉及制备包含公式I化合物的药物组合物以及治疗哺乳动物的疾病和障碍的方法,例如神经退行性和/或神经系统疾病,例如阿尔茨海默病。
查看更多